Genetic testing in urology: who needs it and what it changes

This is the distinction almost every other page skips, and it is the source of most confusion. Germline testing looks at the genes you were born with — a blood or saliva sample that tells you whether you carry an inherited mutation (such as BRCA2) that you could pass to children and that raises cancer risk across your lifetime. This is what people usually mean by "genetic testing."

Somatic (tumor) testing is completely different: it analyzes the cancer tissue itself, usually from a biopsy or surgery sample, to find mutations inside the tumor that may respond to specific drugs. A somatic result describes the cancer, not you, and is not passed to your children — though a mutation found in the tumor sometimes prompts a germline test to check whether it is also inherited.

Prognostic or genomic tests — names like Decipher, Oncotype DX, and Prolaris — are a third category patients often lump in with genetics. They read patterns of gene activity in prostate tissue to estimate how aggressive a cancer is likely to be, helping decide between active surveillance and treatment. They are not tests for inherited risk. Knowing which of these three your doctor is talking about changes everything that follows.

Genetic testing is not for everyone, and undirected testing can create anxiety and ambiguous results without changing care. The strongest reasons to consider germline testing in urology cluster around prostate cancer. National guidelines generally point to men with metastatic prostate cancer, high-risk or very-high-risk localized disease, certain aggressive pathology features, or unusual findings such as intraductal carcinoma.

Family history is the other major trigger, even without a personal cancer diagnosis. Red flags include multiple blood relatives with prostate, breast, ovarian, pancreatic, or colorectal cancer; cancers diagnosed at young ages; a known mutation already identified in the family (such as a BRCA gene); or Ashkenazi Jewish ancestry, which carries higher odds of specific BRCA mutations. Male breast cancer anywhere in the family is a notable flag.

Lynch syndrome deserves a specific mention because it sits squarely in urology's lane: the same mismatch-repair gene changes that drive colorectal and endometrial cancer also raise the risk of upper-tract urothelial cancer (the lining of the kidney and ureter). A personal or family pattern suggesting Lynch can justify testing and, separately, changes how a urologist monitors the urinary tract.

For screening, a positive germline result can move the timeline earlier and the threshold lower. Men who carry a high-risk mutation such as BRCA2 are often advised to begin PSA-based prostate screening at a younger age and to take a rising or borderline PSA more seriously, because the cancers associated with these mutations tend to behave more aggressively.

For treatment, an inherited or tumor mutation can unlock options that would not otherwise be on the table. Mutations in DNA-repair genes (such as BRCA2 and ATM) can make certain advanced prostate cancers responsive to PARP inhibitors, and mismatch-repair defects or high microsatellite instability can open the door to specific immunotherapy. This is why testing is recommended at the point where treatment decisions are being made, not as an afterthought.

For your family, a positive germline result is shared information. First-degree relatives each have roughly a one-in-two chance of carrying the same mutation, and "cascade testing" lets them find out and adjust their own screening — for prostate, breast, ovarian, pancreatic, or colorectal cancer depending on the gene. For many people this family benefit is the single most valuable outcome of testing.

A urologist is frequently the person who first raises genetic testing, because urologists are the ones diagnosing and staging prostate, kidney, and urothelial cancers where the question comes up. In practice a urologist may order germline testing directly, refer you to a genetic counselor first, or order it and bring in a counselor once the result is back — all are legitimate paths.

Genetic counselors and medical oncologists are the other key players. A genetic counselor maps your family tree, decides which test fits, and interprets ambiguous results; a medical oncologist typically leads when results drive systemic cancer treatment. The urologist's distinct contribution is connecting the result to urologic care: adjusting prostate screening, planning surveillance of the upper urinary tract in Lynch syndrome, and coordinating biopsy or surgery samples for tumor testing.

If you think you qualify and no one has raised it, ask directly. A reasonable question is simply, "Given my diagnosis and family history, should I have germline genetic testing, and would you order it or refer me to a counselor?" Guidelines explicitly encourage patients to initiate this conversation when testing may apply.

Genetic counseling is not a formality. Results are rarely a simple yes or no — a common outcome is a "variant of unknown significance," a gene change whose meaning is not yet established and which should not trigger drastic action. A negative result is reassuring but not absolute, because a panel only tests the genes it is designed to look for. Counseling is what keeps both of these from being misread.

On privacy, the federal Genetic Information Nondiscrimination Act (GINA) prevents health insurers and most employers from using your germline results against you. The important limit is that GINA does not extend to life, disability, or long-term-care insurance. None of this applies to tumor (somatic) testing, which describes the cancer rather than your inherited makeup.

Finally, a result is only as useful as the action it informs. Testing earns its place when it can change screening intensity, open a treatment, or protect a relative. When it cannot do any of those — for example, low-risk localized cancer with no concerning family history — many experts advise against routine germline testing, and counseling helps you decide where you fall.